

PUBLICATIONS ONLY

PATENTS EMANATING from LABORATORY and CLINICAL RESEARCH

Cited from SCOPUS

Unites States Patent and Trademark Office [10]
World Intellectual Property Organization [7]
European Patent Office [6]

Patent name	Inventor(s)/applicant(s)	Patent office	Year	Patent number
1 PROTECTION OF PLANT EXTRACTS AND COMPOUNDS FROM DEGRADATION	VITETTA, Luis; HALL, Sean (Medlab IP Pty Ltd)	United States Patent and Trademark Office Pre-Granted Publication	2022	US20220274943
2 COMBINATION THERAPY POLYTHÉRAPIE	HALL, Sean; VITETTA, Luis (MEDLAB IP PTY LTD)	Patent Cooperation Treaty Application	2022	WO2022174305
3 TRANSMUCOSAL AND TRANSDERMAL DELIVERY SYSTEMS	Rutolo, JR., David A.; Hall, Sean Michael; Vitetta, Luis (...) (Medlab Clinical U.S., Inc.)	United States Patent and Trademark Office Pre-Granted Publication	2022	US20220023199
4 TRANSMUCOSAL AND TRANSDERMAL DELIVERY SYSTEMS TRANSMUKOSALE UND TRANSDERMALE FREISETZUNGSSYSTEME	HALL, Sean, Michael; VITETTA, Luis; ZHOU, Yusi (...) (Medlab Clinical U.S., Inc.)	European Patent Application	2021	EP3928763
5 Transmucosal and transdermal delivery systems	Rutolo, Jr., David A.; Hall, Sean Michael; Vitetta, Luis (...) (Medlab Clinical U.S., Inc.)	United States Patent and Trademark Office Granted Patent	2021	US11160753
6 Treatment for depression and depressive disorders	Vitetta, Luis; Coulson, Samantha Maree; Hall, Sean (Medlab IP Pty Ltd)	United States Patent and Trademark Office Granted Patent	2021	US11135181
7 MODULATION OF INTESTINAL MICROBIOTA IN PRE-DIABETES AND TYPE 2 DIABETES	VITETTA, Luis; PALACIOS, Talia (Medlab IP Pty Ltd)	United States Patent and Trademark Office Pre-Granted Publication	2020	US20200345795
8 DIAGNOSTIC AND THERAPEUTIC METHODS FOR TYPE 2 DIABETES	VITETTA, Luis; PALACIOS, Talia (Medlab IP Pty Ltd)	United States Patent and Trademark Office Pre-Granted Publication	2020	US20200281993
9 DIAGNOSTIC AND THERAPEUTIC METHODS FOR TYPE 2 DIABETES DIAGNOSTISCHE UND THERAPEUTISCHE VERFAHREN FÜR DIABETES TYP 2	VITETTA, Luis; PALACIOS, Talia (Medlab IP Pty Ltd.)	European Patent Application	2020	EP3704485
10 MODULATION OF INTESTINAL MICROBIOTA IN PRE-DIABETES AND TYPE 2 DIABETES MODULATION DER INTESTINALEN MIKROBIOTA IN PRÄDIABETES UND TYP-2-DIABETES	VITETTA, Luis; PALACIOS, Talia (Medlab IP Pty Ltd.)	European Patent Application	2020	EP3703719
11 PROTECTION OF PLANT EXTRACTS AND COMPOUNDS FROM DEGRADATION	VITETTA, Luis; HALL, Sean (Medlab IP Pty Ltd)	United States Patent and Trademark Office Pre-Granted Publication	2019	US20190315704
12 MODULATION OF INTESTINAL MICROBIOTA IN PRE-DIABETES AND TYPE 2 DIABETES MODULATION DU MICROBIOTE INTESTINAL DANS LE PRÉ-DIABÈTE ET LE DIABÈTE DE TYPE 2	VITETTA, Luis; PALACIOS, Talia (MEDLAB IP PTY LTD)	Patent Cooperation Treaty Application	2019	WO2019084617

13	DIAGNOSTIC AND THERAPEUTIC METHODS FOR TYPE 2 DIABETES MÉTHODES DE DIAGNOSTIC ET THÉRAPEUTIQUES POUR LE DIABÈTE DE TYPE 2	VITETTA, Luis; PALACIOS, Talia (MEDLAB IP PTY LTD)	Patent Cooperation Treaty Application	2019	WO2019084616
14	PROTECTION OF PLANT EXTRACTS AND COMPOUNDS FROM DEGRADATION SCHUTZ VON PFLANZENEXTRAKTEN UND VERBINDUNGEN VOR VERFALL	VITETTA, Luis; HALL, Sean (Medlab IP Pty Ltd.)	European Patent Application	2019	EP3454849
15	TRANSMUCOSAL AND TRANSDERMAL DELIVERY SYSTEMS	Rutolo, JR., David A.; Hall, Sean Michael; Vitetta, Luis (...) (Medlab Clinical U.S., Inc.)	United States Patent and Trademark Office Pre-Granted Publication	2018	US20180036226
16	TRANSMUCOSAL AND TRANSDERMAL DELIVERY SYSTEMS TRANSMUKOSALE UND TRANSDERMALE FREISETZUNGSSYSTEME	HALL, Sean, Michael; VITETTA, Luis; ZHOU, Yusi (...) (Medlab Clinical U.S., Inc.)	European Patent Application	2018	EP3265140
17	PROTECTION OF PLANT EXTRACTS AND COMPOUNDS FROM DEGRADATION PROTECTION D'EXTRAITS VÉGÉTAUX ET DE COMPOSÉS CONTRE LA DÉGRADATION	VITETTA, Luis; HALL, Sean (MEDLAB IP PTY LTD)	Patent Cooperation Treaty Application	2017	WO2017193169
18	TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS	Vitetta, Luis; Coulson, Samantha Maree; Hall, Sean (Medlab IP Pty Ltd)	United States Patent and Trademark Office Pre-Granted Publication	2017	US20170312232
19	TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS BEHANDLUNG VON DEPRESSION UND DEPRESSIVEN STÖRUNGEN	VITETTA, Luis; COULSON, Samantha; HALL, Sean (Medlab IP Pty Ltd.)	European Patent Application	2017	EP3212191
20	TRANSMUCOSAL AND TRANSDERMAL DELIVERY SYSTEMS SYSTÈMES D'ADMINISTRATION TRANSMUQUEUSE ET TRANSDERMIQUE	HALL, Sean, Michael; VITETTA, Luis; ZHOU, Yusi (...) (MEDLAB CLINICAL U.S., INC.)	Patent Cooperation Treaty Application	2016	WO2016141069
21	TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS TRAITEMENT DE LA DÉPRESSION ET DES TROUBLES DÉPRESSIFS	VITETTA, Luis; COULSON, Samantha; HALL, Sean (MEDLAB IP PTY LTD)	Patent Cooperation Treaty Application	2016	WO2016065419
22	PROBIOTIC COMBINATIONS AND USES THEREOF	COULSON, Samantha; HALL, Sean; VITETTA, Luis (Medlab IP Pty Ltd)	United States Patent and Trademark Office Pre-Granted Publication	2015	US20150335688
23	PROBIOTIC COMPOSITIONS AND USES THEREOF FOR TREATMENT OF OBESITY-RELATED DISORDERS COMPOSITIONS PROBIOTIQUES ET LEURS UTILISATIONS POUR LE TRAITEMENT DE TROUBLES LIÉS À L'OBÉSITÉ	VITETTA, Luis; COULSON, Samantha; HALL, Sean (MEDLAB IP PTY LTD)	Patent Cooperation Treaty Application	2015	WO2015172191

PUBLICATIONS

Under Review

Articles

Reuter SE, Schultz HB, Mclachlan AJ, Henson JD, **Vitetta L**. Pharmacokinetics and bioavailability of cannabinoids administered via a novel nanoparticle formulation (NanoCelle™) in patients with advanced cancer. **J Cannabis and Cannabinoid Research**.

Elizabeth Steels, Harry Huntress, Michael J. Zuscik, Susan Bukata, Clifford Rosen, Douglas P. Kiel, Thomas G. Travison, Mark Charbonneau, Gerardo V. Toledo, Eric M. Schott, **Luis Vitetta**. A clinical study to evaluate the efficacy of the medical food, SBD111, versus placebo for the clinical dietary management of postmenopausal bone loss and menopause symptoms in otherwise healthy menopausal women: a randomized, double blind placebo-controlled trial. **Scientific Reports**.

Esben Strodl, Matthew Bambling, Sophie Parnam, Gabrielle Ritchie, Susanna Cram, **Luis Vitetta**. Probiotics and Magnesium Orotate for the Treatment of Major Depressive Disorder: A Randomised Double Blind Controlled Trial. **Scientific Reports**

Theses

1. **Vitetta L**. Biogenesis of mitochondria: physical mapping studies of mitochondrial DNA and RNA through molecular hybridizations. BSc Honors Report, Monash University, Pp 1-58, 1981.
2. **Vitetta L**. Gallstone composition and dissolution: an epidemiological and aetiological study. Vol 1 and 2: Pp 1-475. PhD Thesis, University of Melbourne, Dissertation Abstracts International, 47(6), 1986. Ann Arbor, Michigan, USA.

Chapter in Books [x12]

1. Kune GA, **Vitetta L**. Colorectal Cancer. Chapter 27, Pages: 787-798. In: Testing, Predicting and Interpreting Carcinogenicity. KT Kitchen (ed), Marcel Dekker, NY, 1999. ISBN: 0824798937
2. **Vitetta L**. Nutritional Factors Including Anti-Oxidants in Dementia and Anti-Aging. R Goldman and R Klatz Eds. In: Anti-Aging Therapeutics 2003; Volume VI, Ch 26, Pp 243-248. [An official educational work published by A4M publications] ISBN: 0-9668937-5-1 (print and CD ROM)
3. **Vitetta L**, Anton B, Cortizo F, Sali A. Mind Body Medicine: Stress and its impact on Overall Health and Longevity. In: Reversal of Aging, Myth and Reality: Beyond the Man-Made Barriers. Part VI. Replacement Therapies of a Failing Body: Clinical Evidence of Restorative Medicine: Annals New York Academy of Sciences Volume 1057; 2005; Pp 492-505.
4. Anton B, **Vitetta L**, Cortizo F, Sali A. Can We Delay Aging? The Biology and Science of Aging. In: Reversal of Aging, Myth and Reality: Beyond the Man-Made Barriers. Part VII. Striving for Health—Anti-aging Medicine and Its Presence in the World: The Witnesses and Pioneers of a Rapidly Changing and Aging Western Population: Annals New York Academy of Sciences Volume 1057; 2005; Pp 525-535.
5. **Vitetta L**, Sali A. Mind Body Medicine: The Key to Health and Longevity. Chapter in Book In: Mind Body and Relaxation Research Focus. Nova Press Scientific Publications. De Luca BD, ed., ISBN-10: 1600218199 ISBN-13: 978-1600218194.
6. Hoffman T, Bennett JW, Elkins MR, Lockwood C, Morgan A, Sanders S, Spencer A, **Vitetta L**, Wright C. Questions About the Effects of Interventions: Examples of Appraisals from Different Health Professions. Chapter in Book In: Evidence-Based Practice Across the Health Professions. Churchill Livingston Publications. Eds. Hoffman T, Bennett S, Del Mar C, Ch5; 96-127. 2009. ISBN: 978-0-7295-3902-9.

Solicited book chapters from Springer, Basel AG.

7. **Vitetta L**, Hall S, Palacios T Coulson S. Pp 1-34. Gastrointestinal Tract Commensal Bacteria and Probiotics: Influence on End-Organ Physiology. In: Progress in Drug Research Novel Natural Products: Therapeutic Effects in Pain, Arthritis And Gastro-Intestinal Diseases [Editors: KD Rainsford, MC Powanda and MW Whitehouse] Publisher: Springer Basel AG. 2015. ISBN 978-3-0348-0926-9
8. Coulson S, Palacios T, **Vitetta L**. Pp 91-132. *Perna canaliculus* (Green Lipped Mussel): Bioactive Components and Therapeutic Evaluation for Chronic Health Conditions. In: Progress in Drug Research Novel Natural Products: Therapeutic Effects in Pain, Arthritis and Gastro-Intestinal Diseases [Editors: KD Rainsford, MC Powanda and MW Whitehouse] Publisher: Springer Basel AG. 2015. ISBN 978-3-0348-0926-9.
9. Alex Seungyeon Byun, **Vitetta L**, Hak-Kim Chan, Philip Chi Lip Kwok. Respiratory delivery of probiotics to improve lung health. In: Respiratory Delivery of Biologics, Nucleic Acids, and Vaccines. Springer Link. Eds J Lam, Philip Chi Lip Kwok. 2023; Ch 7; 149-172.

Solicited book chapters from Elsevier.

10. Sali A, **Vitetta L**. Aging. In: General Practice: The Integrative Approach. Elsevier Ltd. Eds Phelps K., Hassad C. 2010; Ch 58 Pp 841-857. ISBN: 9780729538046.
11. **Vitetta L**, Ciccutini F, Sali A. Alternative Therapies for Musculoskeletal Conditions. In: Best Practice and Research in Clinical Rheumatology. Brooks P, Conaghan, P. eds. Elsevier Science Ltd.
12. **Vitetta L**, Clark S. Intestinal Bacteria and Cancer. In: Modulation of the microbiome for immunotherapy. Elsevier.

Solicited Text-Book [x1]

1. Kotsirilos V, **Vitetta L**, Sali A. A guide to evidence based integrative and complementary medicine. Eds. Kotsirilos V, Vitetta L, Sali A. Elsevier 2010, p1-956. Sydney, Australia. ISBN: 9780729539081.

Commercial Requests and Consultancy Reports [x6]

1. **Vitetta L**, Paspaliaris B, Johnson M, Sali A. Cigarrest – a herbal tonic for cigarette and smoking cessation. Kepper Holdings 2001.
2. **Vitetta L**, Johnson M, Sali A. Contact Thermography Biological Therapies 2002
3. **Vitetta L**, Paspaliaris B, Johnson M, Sali A. The integrated inpatient management program for people with cancer: the scientific evidence and methodology to be employed 2002.
4. **Vitetta L**, Paspaliaris B, Johnson M, Cortizo F, Sali A. Body Enhancer: Product by Zenith Corporation (NZ) – The Scientific Evidence Part I 2002.
5. **Vitetta L**, Cortizo F, Sali A. Body Enhancer: Product by Zenith Corporation Ltd (NZ). The Scientific and Clinical Evidence: Part II. 2003
6. **Vitetta L**, Cortizo F, Sali A. Body Enhancer: Product by Zenith Corporation Ltd (NZ). Assessment of Clinical Trial Data. Part III. 2004.

Literature Reviews – Funded / Solicited [x10]

1. Kissane DW, White K, Cooper K, **Vitetta L**. The Psychosocial impact in the areas of body image and sexuality for women with breast cancer. Publication for NHMRC National Breast Cancer Center Australia 2003. ISBN Print: 1 876319 78 X
2. **Vitetta L**, Gersh W, Johnson M, Mrazek L, Sali A. A National Needs Assessment of Parents of Children/Adolescents with Inflammatory Bowel Disease: Crohns Disease and Ulcerative Colitis. Publication for Australian Crohns and Colitis Association 2001
3. **Vitetta L**, Johnson M, Reavley N, Sali A. Psychosocial support of cancer patients. Publication for Federal Department of Veterans Health 2002.
4. **Vitetta L**, Coulson S, Beck S. Survey of Known Probiotics [Species / Strains] and Prebiotics with a Potential Health Benefit and Immunogenic Effects. Parmalat Review. February 2010.
5. **Vitetta L**, Beck SL, Coulson S, Trabi M. Black Cohosh [known as both *Actaea racemosa L.* and *Cimicifuga racemosa L.*]: Scientific Evaluation for Suspected Liver Toxicity. 2011. Part I. Swisse Multivitamins Pty Ltd
6. Trabi M, **Vitetta L**. Analysis of Women's Ultivite Preparations and *Cimifuga Racemosa* extracts. 2011. Part II. Swisse Multivitamins Pty Ltd
7. **Vitetta L**. Circulating tumour cells in clinical practice – is there scientific plausible evidence for analytical testing? 2011.
8. **Vitetta L**. Scientific literature review [with additional provision of UQ research laboratory / clinical data pertinent to the review], of the published scientific laboratory and clinical evidence for the use of IV ascorbate [Vitamin C] in the therapeutic treatment of cancer. 2011.
9. **Vitetta L**, Coulson S, Rao A, Steels E. Swisse Vitamins Pty Ltd Products: Scientific / Clinical Evidence and Allowable Claims – A Review. Part I, II and III. 2012.
10. **Vitetta L**. Independent assessment of probiotic systematic reviews for Parmalat Australia. 2019.

Refereed Journal Articles [x164] – Invited Editorials [x28] – Commentaries / Correspondence [x24]

1. **Vitetta L**, Stubbs A, Purser S, Millar K, Sali A. Limy "milky" bile: without apparent gall-bladder obstruction by a gallstone. Aust NZ J Surg 1987; 57:405-408.
2. **Vitetta L**, Sali A, Chou ST, Fleming H, Little P, Elzarka A. Gallstones at autopsy and cholecystectomy: a comparative study. Aust NZ J Surg 1988; 58:561-568.
3. Kune GA, Kune S, Watson LF, Pierce RJ, Field B, **Vitetta L**. Serum levels of beta-carotene, vitamin A, and zinc in male lung cancer cases and controls. Nutr Cancer 1989; 12:169-176.
4. **Vitetta L**, Sali A, Moritz V, Shaw A, Carson P, Little P, Elzarka A. Bacteria and gallstone nucleation. Aust NZ J Surg 1989; 59:571-577.
5. Sali A, Oats JN, Acton CM, Elzarka A, **Vitetta L**. Effect of pregnancy on gallstone formation. Aust NZ J Obstet Gynaecol 1989; 29:386-389.
6. Gya D, Sali A, **Vitetta L**, Eu P, Arkles B. Limy bile cholecystitis: an in vitro study and a case report. Aust NZ J Surg 1990; 60:998-1000.
7. Sali A, **Vitetta L**. Gallstone decalcification and dissolution using chenodeoxycholate and citrate. HBP Surg 1990; 3:59-65.
8. **Vitetta L**, Sali A, Little P, Nayman J, Elzarka A. Primary "brown pigment" bile duct stones. HBP Surg 1991; 4:209-222.
9. Kune GA, Kune S, **Vitetta L**, Watson LF. Smoking and colorectal cancer risk: data from the Melbourne colorectal cancer study and brief review of literature. Int J Cancer 1992; 50:369-372.
10. Kune GA, **Vitetta L**. Alcohol consumption and the etiology of colorectal cancer: a review of the scientific evidence from 1957 to 1991. Nutr Cancer 1992; 18:97-111.
11. Kune GA, Bannerman S, Field B, Watson LF, Cleland H, Merenstein D, **Vitetta L**. Diet, alcohol, smoking, serum beta-carotene, and vitamin A in male nonmelanocytic skin cancer patients and controls. Nutr Cancer 1992;18:237-244.
12. **Vitetta L**, Sali A. Primary bile duct stones and bacterial activity. HBP Surg 1992; 6:23-33.
13. Kune GA, Kune S, Filed B, Watson LF, Cleland H, Merenstein D, **Vitetta L**. Oral and pharyngeal cancer, diet, smoking, alcohol, and serum vitamin A and beta-carotene levels: a case-control study in men. Nutr Cancer 1993; 20:61-70.
14. Kune GA, **Vitetta L**. Smoking and tobacco as an etiologic factor in gastric carcinoma. Gastrointestinal Cancer 1995;1:33-38.
15. Kune GA, **Vitetta L**. The causes of colorectal adenomas: the key to the control of colorectal cancer. J Royal Soc Med 1995; 88:625-628.
16. Kissane D, Clark D, Ikin J, Bloch S, Smith CS, **Vitetta L**, McKenzie DP. A cross-sectional survey of psychological morbidity and quality of life in Australian women with early stage breast cancer. Med J Aust 1998; 169(4):192-196.
17. **Vitetta L**, Kenner D. Another step for "electronics kind" eBMJ 6 November 1999.
18. Sali A, **Vitetta L**. Nutrition: Essence of a Healthy Life eBMJ 30 November 1999.
19. **Vitetta L**, Kenner D, Kissane D. The design and implementation of a computerized database for the efficient delivery of palliative care: with a brief review of the literature. Progress in Palliative Care 1999; 1:56-63.
20. **Vitetta L**, Sali A. Citrate: a component of bile and calcium chelator in gallbladder disease. J Nutr and Environ Med 1999; 9(3):199-207.
21. Sali A, **Vitetta L**. Complete Medicine—an integrative approach to health care. J Veteran's Health Aust 1999;68:32-33.
22. **Vitetta L**, Sali A. Tobacco on the shelf eBMJ 9 August 2000.
23. **Vitetta L**, Sali A, Reavley N, Sali A. What about nutrition and gestational diabetes. eBMJ 7 September 2000.
24. **Vitetta L**, Sali A, Reavley N, Sali A. A further thought to consider Re: smoking nutrition and gestational diabetes eBMJ 12 September 2000.
25. **Vitetta L**, Sali A, Little P, Mrazek L. Gallstones and Gallbladder Carcinoma. Aust NZ J Surg 2000;70:667-673.
26. **Vitetta L**, Kenner D Sali A. Bacterial infections in terminally ill hospice patients. J Pain and Symptom Manag 2000; 20:326-334.
27. **Vitetta L**, Best S, Sali A. Single and multiple cholesterol gallstones and the influence of bacteria. Medical Hypothesis 2000; 55(6):502-506.

28. Glas R, Reavley N, Mrazek L, **Vitetta L**, Sali A. Psychosocial Interventions and cancer patients: psychological and immune responses may depend on cancer type. *Medical Hypothesis* 2001; 56(4):480-482.
29. **Vitetta L**, Kenner D, Kissane D, Sali A. Clinical outcomes in terminally ill patients admitted to hospice care: diagnostic and therapeutic interventions. *Journal of Palliative Care* 2001; Summer 17(2):69-77.
30. Ellis KA, Stough C, **Vitetta L**, Heinrich K, Nathan PJ. An investigation into the acute nootropic effects of hypericum perforatum L. (St John's Wort) in healthy human volunteers. *Behaviv Pharmacol* 2001;12:173-82.
31. Timoshanko A, Stough C, **Vitetta L**, Nathan PJ. A preliminary investigation on the acute pharmacodynamic effects of hypericum on cognitive and psychomotor performance. *Behavioural Pharmacol* 2001;12(8):635-640.
32. **Vitetta L**, Sali A, Reavley N. Does drinking carrot juice affect cancer of the prostate? *Med J Aust* 2001 175(1):52-3
33. **Vitetta L**, Sali A, Reavley N. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? *Med J Aust* 2001 175(8):447-448.
34. **Vitetta L**, Mrazek L, Sali A. A delay in the onset of obesity? *eBMJ* 5 December 2001.
35. **Vitetta L**, Sali A. Smoking cessation a difficult proposition: not without hope *eBMJ* 12 January 2002
36. **Vitetta L**, Sali A, Paspaliaris B, Reavley N. Mega – dose vitamin C in the treatment of the common cold: randomized controlled trial *Med J Aust* 2002 176(5):298-299.
37. **Vitetta L**, Kenner D, Sali A. As to the intention to hasten death of the terminally ill. *Med J Aust* 2002; 177(1):166-167.
38. **Vitetta L**, Barbaro C, Sali A. Vitamins Health and Scientific Evidence *eBMJ* 30 July 2002
39. **Vitetta L**, Thomsen M, Sali A. Black Cohosh and other herbal remedies associated with acute hepatitis. *Med J Aust* 2003; 178(8): 411-412.
40. Thomsen M, **Vitetta L**, Schmidt M, Sali A. Fatal fulminant hepatic failure induced by a natural therapy containing kava. *Med J Aust.* 2004; 180(4):198-9
41. Thomsen M, **Vitetta L**, Schmidt M, Sali A. Acute liver failure associated with the use of herbal preparations containing black cohosh. *Med J Aust* 2004; 180(11): 598-599.
42. Thomsen M, Schmidt M, **Vitetta L**, Sali A. Do herbs increase the risk of herb-drug interactions for patients with arthritis? *Ann Rheum Dis.* 2005; 64(10):1527.
43. Sali A, **Vitetta L**. Research in Complementary and Alternative Medicine. *Australasian Journal of Integrative Medicine* 2001;1(1): 59-61.
44. **Vitetta L**. Sali A. Integrative Medicine – A New Era with Global Implications for Health and Disease Prevention. *South African Journal of Natural Medicine* 2002;6:16-17.
45. Sali A, **Vitetta L**. Integrative Medicine– Keeping up with the evidence. *Journal Complementary Medicine* 2003; 2(6):36-41.
46. Sali A, **Vitetta L**. Nutritional Supplements and Cardiovascular Disease. *Heart Lung and Circulation Journal* 2004; 13(4):363-366.
47. **Vitetta L**, Sali A. Dementia. *Journal of Complementary Medicine* 2004; 3(1):14-19
48. Cortizo F, **Vitetta L** Functional Foods–Apples and Oats. *Journal of Complementary Medicine* 2004; 3(2):61.
49. Cortizo F, **Vitetta L**. Functional Foods–Soya and Flaxseed. *Journal of Complementary Medicine* 2004; 3(3):50-51.
50. Cortizo F, **Vitetta L**. Functional Foods–Broccoli and Cranberry. *Journal of Complementary Medicine* 2004; 3(4):65-66.
51. **Vitetta L**, Sali A. Placebo myth or reality–its role in clinical trials. *Journal of Complementary Medicine* 2004; 3(6):57-58.
52. Cortizo F, **Vitetta L**. Functional Foods–Teas. *Journal of Complementary Medicine* 2004; 3(6):79-80.
53. Di Vincenzo, **Vitetta L**, Ng F, Sali A. Nutritional and Lifestyle Factors influencing the progression and development of NIDDM in lean adult Vietnamese. *Journal of the Australasian Integrative Medicine Association* 2004; 23:25-30.
54. **Vitetta L**, Sali H, Burke J, Mrazek L, Cortizo F, Sali A. The live blood analysis technique. *Journal of the Australasian Integrative Medicine Association* 2005; 24:16-20.
55. Wang Y, Prentice LF, **Vitetta L**, Wluka AE, Cicuttini FM. Nutrition and dietary supplements and osteoarthritis. *Alternative Medicine Review Journal* 2004; 9(3):275-96.
56. Ellis JR, Ellis KA, Bartholomeuz CF, Harrison BJ, Wesnes KA, Erskine FF, **Vitetta L**, Nathan PJ. Muscarinic and Nicotinic Receptors Synergistically Modulate Working Memory and Attention in Humans. *International Journal of Neuropsychopharmacology* 2005; 9:1-15.
57. **Vitetta L**, Cortizo F, Sali A. Probiotics and Prebiotics in Health: an emerging new modality in biotherapeutics. *Journal of the Australasian Integrative Medicine Association* 2005; 25:18-22.
58. **Vitetta L**, Kenner D, Sali A. Sedation and Analgesia Prescribing Patterns by Physicians in Terminally Ill Patients at the End of Life. *Am J Hosp Palliat Care* 2005; 22(6):465-73.
59. Wang Y, Cicuttini FM, **Vitetta L**, Wluka AE. What effect do dietary antioxidants have on the symptoms and structural progression of knee osteoarthritis over 2 years? *Clin Exp Rheumatol* 2006; 24(2):213-4.
60. **Vitetta L**, Sali A. Complementary Medicine Series: What is the evidence. Colorectal cancer and CHF - reviewing the evidence for complementary medicine. *Aust Fam Physician.* 2006; 35(5):339.
61. **Vitetta L**, Sali A. Complementary Medicine Series: What is the evidence. Treatments for damaged skin. *Aust Fam Physician* 2006; 35(7):501-2.
62. **Vitetta L**, Sali A. Complementary Medicine Series: What is the evidence. Complementary and Alternative Medicine and Palliative Care. *Aust Fam Physician* 2006; 35(10):783.
63. **Vitetta L**. Invited Commentary – Psychoneuroimmunology and occupational therapy for inflammatory disorders. *Intern J Ther Rehabil* 2006;13(11):510.
64. **Vitetta L**, Sali A. Omega–3 Fatty Acids PUFA - A Review PART I. *Journal of Complementary Medicine* 2006; 5(6):52-59.
65. Linnane AW, Kios M, **Vitetta L**. The Essential Roles of Superoxide Radical and Nitric Oxide Formation for Healthy Aging. *Mitochondrion* 2007; 7(1-2):1-5.
66. **Vitetta L**, Sali A. Complementary Medicine Series: What is the evidence. Complementary and Alternative Medicine. Integrative medicine in gynaecological cancers. *Aust Fam Physician.* 2007;36(3):135-6.
67. **Vitetta L**, Sali A. Omega–3 Fatty Acids PUFA - A Review PART II. *Journal of Complementary Medicine* 2007; 6:48-52.
68. Linnane AW, Kios M, **Vitetta L**. Healthy Aging: Regulation of the Metabolome by Cellular Redox Modulation and Prooxidant Signaling Systems. The Essential Roles of Superoxide Anion and Nitric Oxide. *Biogerontology* 2007;8:445-67.
69. Linnane AW, Kios M, **Vitetta L**. Coenzyme Q10 - Its role as a Prooxidant in the Formation of Superoxide Anion / Hydrogen Peroxide and the Regulation of the Metabolome. *Mitochondrion.* 2007; Suppl 1:S51-61.

70. **Vitetta L**, Anton B. Lifestyle and Nutrition, Caloric Restriction, Mitochondrial Health and Hormones: Scientific Interventions for Anti-Aging. *J Clinical Interventions in Aging* 2007;2(4):537-543.
71. Sali A, **Vitetta L**. Complementary Medicine Series: What is the evidence. *Complementary and Alternative Medicine and Arrhythmia. Austr Fam Physician* 2007;36(7):527-8.
72. Sali A, **Vitetta L**. Peppermint and the gut. *Medicine Today* 2007;8(5):67-69.
73. **Vitetta L**, Sali A. Palliative Care. *Nutritional Approaches. J Compl Med* 2007; 6(4):16-26.
74. **Vitetta L**, Sali A. Life Stressors: Nutritional choices and obesity. *Journal Australasian Integrative Medicine Association* 2007; 12(3):8-13.
75. Sali A, **Vitetta L**. Integrative Medicine: In the Mix. *Australian Doctor* 2007; 20 April:39-40.
76. Sali A, **Vitetta L**. Therapy Update, Integrative Medicine: Management of Coronary Artery Disease. *Australian Doctor* 2007; 15 June: 39-43.
77. Sali A, **Vitetta L**. Therapy Update, Integrative Medicine: Management of Prostate Cancer. *Australian Doctor* 2007; 21 September: 35-36.
78. Sali A, **Vitetta L**. Therapy Update, Integrative Medicine: Tackling Osteoarthritis. *Australian Doctor* 2007; 23 November:41-45.
79. Sali A, **Vitetta L**. Therapy Update, Integrative Medicine: Diabetes under assault. *Australian Doctor* 2008; 4 April: 39-41.
80. Sali A, **Vitetta L**. Therapy Update, Integrative Medicine: Infertile. *Australian Doctor* 2008; 29 August: 38.
81. Sali A, **Vitetta L**. Care of the Cancer Patient by the General Practitioner (GP). *J Complementary Medicine* 2008; 7(2):28-29.
82. **Vitetta L**. Oxidative Stress and Antioxidants. *J Complementary Medicine* 2008;7(2):22- 25.
83. **Vitetta L**, Sali A. Probiotics, Prebiotics and Gastrointestinal Health. *Medicine Today* 2008;9:65-70.
84. **Vitetta L**, Ciccutini F, Sali A. Alternative therapies for musculoskeletal conditions, *Best Practice and Research Clinical Rheumatology* 2008; 22(3):499-522.
85. Pipingas A, Silberstein RB, **Vitetta L**, Van Rooy C, Harris EV, Young JM, Frampton CM, Sali A, Nastase J. Improved cognitive performance after dietary supplementation with a *Pinus radiata* bark extract formulation. *Phytother Res* 2008;22(9):1168-74.
86. Bartholomeusz CF, Wesnes KA, Kulkarni J, **Vitetta L**, Croft RJ, Nathan PJ. Estradiol Treatment and its Interaction with the Cholinergic System: Effects on Cognitive Function in Healthy Young Women. *Horm Behav* 2008;54:684-93.
87. Zhang AL, Story DF, Lin V, **Vitetta L**, Xue CC. A population survey on the use of 24 common medicinal herbs in Australia. *Pharmacoepidemiol Drug Saf* 2008;17(10):1006-13.
88. Kaur S, Mitchell G, **Vitetta L**, Roberts MS. Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. *Drugs Aging* 2009;26(12):1013-28.
89. **Vitetta L**, Sali A, Coulson S, Gray B. Integrative management of type 2 diabetes mellitus. *JAIMA* 2010;15(2):6-13.
90. Steels E, Rao A, **Vitetta L**. Physiological Aspects of Male Libido Enhanced by Standardized *Trigonella foenum-graecum* Extract and Mineral Formulation. *Phytother Res* 2010; DOI: 10.1002/ptr.3360.
91. **Vitetta L**, Beck S, Coulson S, Sali A. Is it ethical for medical practitioners to prescribe alternative and complementary treatments? *MJA* 2011;195(8):450-451.
92. **Vitetta L**, Sali A, Coulson S. Soy and health: the latest evidence. *Medicine Today* 2011;12(3): 67-74.
93. Harris E, Kirk J, Rowsell R, **Vitetta L**, Sali A, Scholey AB, Pipingas A. The effect of multivitamin supplementation on mood and stress in healthy older males. *Human Psychopharmacology: Clinical and Experimental* 2011; 26:560-7.
94. Schoendorfer N, Tinggi U, Sharp N, Boyd R, **Vitetta L**, Davies PSW. Micronutrient intakes in orally and enterally fed children with severe Cerebral Palsy. *Clinical Nutrition eSPEN* 2011;6(6):e259-e263.
95. Schloss J, **Vitetta L**. Commentary: Cancer Chemotherapeutics, Chemotherapy Induced Peripheral Neuropathy (CIPN) and B Group Vitamins. *ACNEM Journal* 2012;31(2):24-28.
96. Schoendorfer N, Tinggi U, Sharp N, Kahlon P, Yates H, Boyd R, **Vitetta L**, Davies PSW. Protein levels in enteral feeds: Do these meet requirements in children with severe Cerebral Palsy *Br J Nutr* 2012;107:1476–1481.
97. Schoendorfer NC, Obeid R, Moxon-Lester L, Sharp N, **Vitetta L**, Boyd RN, Davies PS. Methylation capacity in children with severe cerebral palsy. *Eur J Clin Invest* 2012;42 (7):768–776.
98. Coulson S, Vecchio P, Gramotnev H, **Vitetta L**. Green-Lipped Mussel (*Perna canaliculus*) Extract Efficacy in Knee Osteoarthritis and Improvement in Gastrointestinal Dysfunction: A Pilot Study. *Inflammopharmacology* 2012;20(2):71-6.
99. **Vitetta L**, Briskey D, Hayes E, Shing, C, Peake J. Probiotics, Commensal Bacteria and the Pharmacobiotic Regulation of Gastrointestinal Inflammation. *Inflammapharmacology* 2012;20(5):251-266.
100. Harris E, McPherson H, **Vitetta L**, Kirk J, Sali A, Pipingas A. Effects of a multivitamin, mineral and herbal supplement on cognition and blood biomarkers in older males: A randomised, placebo-controlled trial. *Human Psychopharmacology* 2012; 27(4):370-7.
101. **Vitetta L**, Coulson S, Schloss J, Beck AL, Allen R, Sali A. Dietary recommendations for patients with rheumatoid arthritis: a review. *Nutr Dietary Supplem* 2012;4:1–15.
102. O'Brien K, **Vitetta L**. Potential role of botanicals for the treatment of chronic stable angina pectoris due to coronary heart disease. *Botanics: Targets and Therapy* 2012;3:1-17.
103. Coulson S, Butt H, Vecchio P, Gramotnev H, **Vitetta L**. Green-Lipped Mussel extract (*Perna canaliculus*) and Glucosamine sulphate in patients with knee Osteoarthritis: therapeutic efficacy and effects on gastrointestinal microbiota profiles. *Inflammopharmacology* 2013;21(1):79-90.
104. Schoendorfer N, **Vitetta L**, Sharp N, Di Geronimo M, Wilson G, Coombes J, Boyd R, Davies PSW. Micronutrient, antioxidant and oxidative stress status in children with severe Cerebral Palsy. *JPEN J Parenter Enteral Nutr* 2013;37:97-101.
105. **Vitetta L**, Coulson S, Beck SL, Gramotnev H, Sharon Du S, Lewis S. Clinical Efficacy of a Bovine Lactoferrin / Whey Protein Ig-rich Fraction (Lf/IgF) for the Prevention of the Common Cold. *J Comp Ther in Medicine* 2013; 21(3):164-71.
106. Coulson S, Rao A, Beck SJ, Steels E, Gramotnev H, **Vitetta L**. A phase IIa randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. *J Comp Ther in Medicine* 2013;21(3):172-9.
107. **Vitetta L**, Gobe G. Uremia and Chronic Kidney Disease: The Role of Probiotics / Prebiotics. *Molecular Nutrition and Food Research* 2013; 57(5):824-32.
108. Marx WM, Teleni LX, McCarthy AL, **Vitetta L**, McKavanagh D, Thomson T, Isenring E. Ginger (*Zingiber officinale*) and chemotherapy-induced nausea and vomiting: a systematic literature review. *Nutrition Reviews* 2013; 71(4):245-54.

109. Schloss JM, Colosimo M, Airey C, Masci PP, Linnane A, **Vitetta L**. Nutraceuticals and Chemotherapy Induced Peripheral Neuropathy (CIPN): a Systematic Review. *Clinical Nutrition* 2013;32(6):888-893.
110. Palacios T, Coulson S, Butt H, **Vitetta L**. The Gastrointestinal Microbiota and Multi-Strain Probiotic Therapy: In Children and Adolescent Obesity. *Advances Integrative Medicine* 2014;1:2-8.
111. Bella CJ, Coulson S, **Vitetta L**. Is co-prescribing a multi-strain probiotic the simple solution for treating and preventing Proton Pump Inhibitor (PPIs) induced *Clostridium difficile* Associated Diarrhoea (CDAD) while maintaining evidence-based pharmacotherapy? *Advances Integrative Medicine* 2014;1:52-54.
112. Gray B, **Vitetta L**, Davies WP. Waist circumference and liver enzymes better predictors of adiponectin levels than BMI in overweight and obese adults. *Nutrition Research* 2013;33(10):781-788.
113. Shing CM, Peake J, Lim CL, Briskey D, Walsh NP, Fortes MB, Ahuja K, **Vitetta L**. Probiotic supplementation improves exercise performance in the heat. *European Journal of Applied Physiology*. 2013; 114(1):93-103.
114. Gray B, Steyn F, Davies PSW, **Vitetta L**. Omega-3 fatty acids: A review of the effects on adiponectin and leptin and potential implications for obesity management. *European Journal of Clinical Nutrition*. 2013;67(12):1234-42.
115. **Vitetta L**, Alford H. The Pharmacobiotic Potential of the Gastrointestinal Tract Micro-Biometabolome—Probiotic Connect: A Brief Commentary. *Drug Development Research* 2013;74:353-359.
116. **Vitetta L**, Linnane AW, Gobe GC. From the Gastrointestinal Tract (GIT) to the Kidneys: Live Bacterial Cultures (Probiotics) Mediating Reductions of Uremic Toxin Levels via Free Radical Signaling. *Toxins* 2013;5(11): 2042-2057.
117. **Vitetta L**, Coulson S, Linnane AW, Butt H. The Gastrointestinal Microbiome and Musculoskeletal Diseases: Is There a Role for Probiotics and Prebiotics? *Pathogens* 2013;2:606-626.
118. Coulson S, **Vitetta L**. A response to AIMA newsletter published 21st Jan 2014. Re: Multivitamins study.
119. **Vitetta L**, Linnane AW. Endocellular regulation by free radicals and hydrogen peroxide: key determinants of the inflammatory response. *Inflammopharmacology*. 2014; 22(2):69-72.
120. Scholoss, J, **Vitetta L**. Antioxidants to Abrogate Free Radicals: a billion-dollar industry based on a chimeric notion without biological plausibility. New insights to challenge currently held beliefs. *Austral J of Herbal Med* 2014;26(1):4-6, 33.
121. **Vitetta L**, Briskey B, Alford H, Hall S, Coulson S. Probiotics and prebiotics and the gastrointestinal tract in health and disease. *Inflammopharmacology* 2014; 22(3):135-54.
122. **Vitetta L**, Hall S, Linnane AW. Live Probiotic Cultures and the Gastrointestinal Tract: Symbiotic Preservation of Tolerance Whilst Attenuating Pathogenicity. Invited Commentary. *Frontiers in Cellular and Infection Microbiology*. 2014; 4:143
123. **Vitetta L**, Linnane AW. Endocellular Regulation of Free Radicals and Hydrogen Peroxide: Key Determinants of the Inflammatory Response. *Inflammopharmacology* 2014;22(2):69-72.
124. Marx W, McCarthy A, Ried K, **Vitetta L**, McKavanagh D, Thomson D, Sali A, Isenring E. Can ginger ameliorate chemotherapy-induced nausea? A double blind, randomised placebo controlled trial. *Trials Journal* 2014;14(1):134.
125. Gray B, Steyn F, Davies WP, **Vitetta L**. Liver function parameters, cholesterol and phospholipid alpha linoleic acid predict adipokine levels in overweight and obese adults. *Nutrition Research* 2014; 34(5):375-82
126. **Vitetta L**, Manuel R, Zhou JY, Linnane AW, Hall S, Coulson S. The Overarching Influence of the Gut Microbiome on End-Organ Function: The Role of Live Probiotic Cultures. *Pharmaceuticals* 2014;7:954-989.
127. **Vitetta L**, Bambling M, Alford H. The Gastrointestinal Tract Microbiome, Probiotics and Mood. *Inflammopharmacology* 2014;22(6):333-9.
128. **Vitetta L**, Hall S, Linnane AW. Live Probiotic Cultures and the Gastrointestinal Tract: Symbiotic Preservation of Tolerance Whilst Attenuating Pathogenicity. *Frontiers in Cellular and Infection Microbiology* 2014 Oct 15;4:143
129. Liu X, **Vitetta L**, Kostner KM, Crompton D, Williams GM, Brown WJ, Lopez A, Xue C, Po Oei T, Byrne G, Martin J, Whiteford HA. The Effects of Tai Chi in Centrally Obese Adults with Depression Symptoms. *Evidence-Based Complementary and Alternative Medicine Volume 2015*, Article ID 879712, 8 pages <http://dx.doi.org/10.1155/2015/879712>.
130. Schloss JM, Colosimo M, Airey C, **Vitetta L**. Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Vitamin B12 Deficiency. *Supportive Care in Cancer*. 2015;23(7):1843-50.
131. Rao A, Steels E, Beccaria G, Inder WJ, **Vitetta L**. Influence of a Specialized Trigonellafoenum graecum Seed Extract (Libifem), on Testosterone, Estradiol and Sexual Function in Healthy Menstruating Women, a Randomised Placebo Controlled Study. *Phytother Res* 2015; 29(8):1123-30.
132. Bambling M, Edwards SC, Coulson S, **Vitetta L**. S-adenosylmethionine (SAME) and Magnesium Orotate as adjunctives to SSRIs in sub-optimal treatment response of depression in adults; a pilot study. *Adv Integrative Medicine* 2015;2:56-62.
133. **Vitetta L**. Lactobacillus acidophilus Restores Functionality in Uremic Macrophages: Plausible or Lacking Evidence? *Dig Dis Sci* 2016;61(6):1417-9.
134. Ellis RJ, Small DM, Vesey DA, Johnson DW, Francis R, **Vitetta L**, Gobe GC, Morais C. Indoxyl sulphate and kidney disease: causes, consequences and interventions. *Nephrology (Carlton)*. 2016;21(3):170-177.
135. Morais C, **Vitetta L**. Journal of Controversies in Biomedical Research- the Need of the Hour. *Journal of Controversies in Biomedical Research* 2015; 1(1):1-3.
136. **Vitetta L**, Coulson S, Linnane AW. Reactive oxygen species in disease: rebuttal of a conventional concept. *Journal of Controversies in Biomedical Research* 2015;1(1):23-27.
137. Schloss J, Colosimo M, **Vitetta L**. New Insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy: Asia-Pacific Journal of Oncology Nursing 2016; 3(1):73-85.
138. **Vitetta L**, Hall S, Coulson S. Metabolic Interactions in the Gastrointestinal Tract (GIT): Host, Commensal, Probiotics, and Bacteriophage Influences. *Microorganisms* 2015;3(4):913-932.
139. Chen C, Zhao KN, Masci PP, Lakhani SR, Antonsson A, Simpson PT, **Vitetta L**. TGF β isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications. *BMC Cancer*. 2015 Dec 24;15(1):1010.
140. Rao A, Steels E, Inder WJ, Abraham S, Vitetta L. Testofen, a specialised Trigonella foenum-graecum seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a double-blind randomised clinical study. *Aging Male* 2016;19(2):134-142.

141. Liu X, Furuya-Kanamori L, Siskind D, Crompton D, Williams GM, Kostner K, **Vitetta L**, Doi SA. An evidence-based scale for the antecedents of depressive symptoms in Australian adults. *Australas Psychiatry*. 2016;24(5):466-469.
142. Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, Crawford D, Campbell C, **Vitetta L**. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. *Therap Adv Gastroent* 2016;9(4):463-72.
143. Schloss J, Colosimo M, Airey C, Masci P, Linnane A, **Vitetta, L**. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). *Supportive Care in Cancer* 2016;25(1):195-204.
144. **Vitetta L**, Saltzman ET, Nikov T, Ibrahim I, Hall S. Modulating the Gut Micro-Environment in the Treatment of Intestinal Parasites. *J Clin Med* 2016;5(11) pii: E102.
145. Schloss J, Colosimo M, **Vitetta L**. Herbal Medicines and Chemotherapy Induced Peripheral Neuropathy (CIPN): a Critical Review. *Critical Reviews in Food Science and Nutrition* 2017;57(6):1107-1118.
146. Marx W, Ried K, McCarthy A, **Vitetta L**, Sali A, McKavanagh D, Isenring E. Ginger - mechanism of action in chemotherapy-induced nausea and vomiting: a review. *Critical Reviews in Food Science and Nutrition*. 2017;57(1):141-146.
147. Palacios T, **Vitetta L**, Coulson S, Madigan CD, Denyer GS, Caterson ID. The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized double-blind placebo-controlled pilot study. *Trials*. 2017;18(1):7
148. **Vitetta L**, Coulson S, Thomsen M, Nguyen T, Hall S. Gut Microbes Manuscript Type: Commentary and Views Submission. Probiotics, D-Lactic Acidosis, Oxidative Stress and Strain Specificity. *Gut microbes*. 2017;12:1-12.
149. Bambling M, Edwards SC, Hall S, **Vitetta L**. A combination of probiotics and magnesium orotate attenuate depression in a small SSRI resistant cohort: an intestinal anti-inflammatory response is suggested. *Inflammopharmacology*. 2017; 25(2):271-274.
150. Heritage ML, Jaskowski LA, Bridle KR, Campbell C, Briskey D, Britton LJ, Fletcher LM, **Vitetta L**, Nathan Subramaniam V, Crawford DHG. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in *Hfe^{-/-}* mice. *World Journal of Gastrointestinal Pathophysiology* 2017; 8(2):67-76.
151. Saltzman, ET, Thomsen M, Hall S, **Vitetta L**. Perna canaliculus and the Intestinal Microbiome. *Mar Drugs* 2017;15(7):pii:E207.
152. Marx W, McCarthy AL, Ried K, McKavanagh D, **Vitetta L**, Sali A, Lohning A, Isenring E. The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial. *Nutrients* 2017;9(8). pii: E867.
153. Detering M, Steels E, Koyyalamudi SR, Alliffranchini E, Bocchietto E, **Vitetta L**. *Ageratum conyzoides* L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study. *Biofactors* 2017;43(6):789-800.
154. **Vitetta L**, Saltzman ET, Thomsen M, Nikov T, Hall S. Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes. *Vaccines* 2017;5:50.
155. **Vitetta L**, Saltzman ET, Thomsen M, Nikov T, Hall S. Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes. *Vaccines (Basel)*. 2017;5(4). pii: E50.
156. **Vitetta L**. Probiotics Can Break the Toxic Relationship Between the Intestinal Microbiome and the Kidney. *Dig Dis Sci* 2018; 64(2):297-299.
157. **Vitetta L**, Zhou J, Manuel R, Dal Forno S, Hall S, Rutolo D Route and Type of Formulation Administered Influences the Absorption and Disposition of Vitamin B₁₂ Levels in Serum. *J Funct Biomater*, 2018;9(1):pii: E12.
158. Saltzman ET, Palacios T, Thomsen M, **Vitetta L**. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. *Front Microbiol* 2018;9:61. eCollection.
159. **Vitetta L**, Vitetta G, Hall S. The Brain-Intestinal Mucosa-Appendix- Microbiome-Brain Loop. *Diseases*. 2018;6(2). pii: E23
160. Ellis RJ, Small DM, Ng KL, Vesey DA, **Vitetta L**, Francis RS, Gobe GC, Morais C. Indoxyl sulfate induces apoptosis and hypertrophy in human kidney proximal tubular cells. *Toxicologic Pathology* 2018;46(4):449-459.
161. Correction: **Vitetta L**, et al., Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes. *Vaccines* 2018;6(2):pii:E26.
162. Chen J, **Vitetta L**. Inflammation-Modulating Effect of Butyrate in the Prevention of Colon Cancer by Dietary Fiber Clin Colorectal Cancer. 2018;7(3):e541-e544.
163. Thomsen M, Clarke S, **Vitetta L**. The Role of Adjuvant Probiotics to Attenuate Intestinal Inflammatory Responses due to Cancer Treatments. *Beneficial Microbes*, 2018;20:1-18.
164. Chen J, **Vitetta L**. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of NAFLD and potential therapeutic implications of probiotics. *Journal of Cellular Biochemistry*, 2018;120(3):2713-2720.
165. **Vitetta L**, Vitetta G, Hall S. Immunological Tolerance and Function: Bacteria, Probiotics, Prebiotics and Phages. *Frontiers in Immunology*, 2018;9:2240.
166. Chen J, **Vitetta L**. Comments on "Supplementation with *Lactobacillus reuteri* ATCC PTA 4659 in patients affected by acute uncomplicated diverticulitis: a randomized double-blind placebo-controlled trial. *Internat J Colorect Dis* 2019; 3498):1503-1504.
167. Chen J, **Vitetta L**. Activation of T-regulatory cells by a synbiotic may be important for its anti-inflammatory effect. *Eur J Nutr* 2019;58(8):3379-3380.
168. Chen J, **Vitetta L**. Bile acids and butyrate in the effects of probiotics/synbiotics on NAFLD. *Eur J Gastroenterol and Hepatol* 2019;31(11):1475-1476.
169. Chen J, Thomsen M, **Vitetta L**. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. *J Cell Biochem*, 2019;120(3):2713-2720.
170. **Vitetta L**, Leong A, Zhou J, Dal Forno S, Hall S, Rutolo D. The Plasma Bioavailability of Coenzyme Q₁₀ Absorbed from the Gut and the Oral Mucosa. *J Funct Biomater* 2018;9(4):pii: E73.
171. **Vitetta L**, Chen J, Clarke S. The vermiform appendix: an immunological organ sustaining a microbiome inoculum. *Clinical Science*, 2019;133(1):1-8.
172. Steels E, Venkatesh R, Steels E, Vitetta G, **Vitetta L**. A double-blind randomized placebo-controlled study assessing safety, tolerability and efficacy of Palmitoylethanolamide for symptoms of knee osteoarthritis. *Inflammopharmacol* 2019;27(3):475-485.

173. Chen J, Zhao KN, **Vitetta L**. Effects of Intestinal Microbial-Elaborated Butyrate on Oncogenic Signaling Pathways. *Nutrients* 2019;11(5):pii: E1026.
174. Thomsen M, **Vitetta L**. Zinc deficiency and mucositis – is there a relationship? *Curr Opin Clin Nutr Metab Care* 2019; Jul 16.
175. **Vitetta L**, Llewellyn H, Oldfield D. Gut Dysbiosis and the Intestinal Microbiome: Is *Streptococcus thermophilus* Key to Reducing Uremia? *Microorganisms* 2019; Jul 31;7(8):pii: E228.
176. Chen J, **Vitetta L**. Mitochondria could be a key mediator in the effect of intestinal microbiota on depression. *Journal of Cellular Biochemistry* 2020;121(1):17-24.
177. Chen J, **Vitetta L**. Signalling molecules and epigenetic targeting in cancer immunotherapy - Comments on "Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma". *Cellular Immunology*. 2019;346:103957.
178. **Vitetta L**, Henson JD. Probiotics and Synbiotics Targeting the Intestinal Microbiome Attenuate Nonalcoholic Fatty Liver Disease (NAFLD). *Hepatobiliary Surgery and Nutrition* 2020; 9(4):526-529.
179. **Vitetta L**. Mind Body Medicine: A Tangible Link Between the Gut and the Brain. *Annals of Translational Medicine* 2020;8(4):64.
180. Chen J, **Vitetta L**. The Role of Butyrate in Attenuating Pathobiont-Induced Hyperinflammation. *Immune Network* 2020;20(2):e15.
181. **Vitetta L**, Butcher B, Del Forno S, Vitetta G, Nikov T, Hall S, Steels E. A double-blind randomized placebo-controlled study assessing the safety, tolerability and efficacy of a herbal medicine containing pycnogenol combined with papain and aloe vera in the prevention and management of pre-diabetes. *Medicines* 2020;7(4):22
182. Chen J, **Vitetta L**. Should butyrate be incorporated into FXR agonist for PSC treatment? Commentary on: FXR agonist Cilofexor improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. *Hepatology* 2020.
183. Chen J, **Vitetta L**. Gut microbiota and therapeutic intervention for NAFLD. Invited Review. *Intern J Mol Sci* 2020.
184. Chen J, Sali A, **Vitetta L**. The gallbladder and vermiform appendix influence the assemblage of intestinal microorganisms. *Future Microbiol* 2020;15:541-555.
185. Palacios T, **Vitetta L**, Coulson S, Madigan CD, Lam YY, Manuel R, Briskey D, Hendy C, Ishoey T, Soto J, Kim J, Schott E, Toledo G and Caterson ID. The effect of a multi-strain probiotic on metabolic and inflammatory markers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: a randomised controlled pilot study. *Nutrients* 2020;12(7):E2041.
186. Chen J, **Vitetta L**. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. *Intern Journal Mol Sci* 2020;21(15):5214.
187. Osborne SA, Du QS, Masci PP, Daniel RA, Desilva K, **Vitetta L**, Zhao KN, Seymour RB. Oral administration of dermatan sulfate from bovine collagen waste liquor reduces venous thrombus formation *in vivo*. *Inflammopharmacology* 2020;29(2):525-535.
188. Chen J, Hall S, **Vitetta L**. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. *Med Rev Virol* 2021;31(5):1-13.
189. Chen J, **Vitetta L**. Increased PD-L1 expression may be associated with the cytokine storm and CD8+ T-cell exhaustion in severe Covid-19. *Journal of Infectious Diseases* 2021;223(9):1659-1660.
190. Chen J, **Vitetta L**. Gut-brain axis in the neurological complications of COVID-19. *Brain Commun* 2021; May 27;3(2):fcab118.
191. Daniels K, **Vitetta L**, Fiatarone Singh M. Effects of olives and their constituents on the expression of ulcerative colitis: a systematic review of murine model trials. *Br J Nutrition* 2021; Jun 8: 1-19.
192. **Vitetta L**, Sikali JF. Comment on: Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in patients with chronic pain. *Can J Anaesth* 2021;68(11):1707-1708.
193. **Vitetta L**, Butcher B, Henson JD, Rutolo D, Hall S. A Pilot Safety, Tolerability and Pharmacokinetic Study of Oro-buccal Administered Cannabidiol Dominant Formulation in Healthy Individuals: A Randomized Placebo Controlled Single-Blinded Study. *Inflammopharmacol* 2021;29(5):1361-1370.
194. Chen J, **Vitetta L**. The gut-liver axis in chronic liver disease - associated with severe COVID-19. *Eur J Gastroenterol Hepatol* 2021; 33(15 Suppl 1):e1103.
195. Chen J, **Vitetta L**. Comment on: Microbiome signatures of progression toward celiac disease onset in at-risk children in a longitudinal prospective cohort study. *PNAS USA* 2021; Oct 12;118(41):e2113655118.
196. Chen J, **Vitetta L**, Henson JD, Hall S. The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. *J Funct Foods* 2021 Dec; 87:104850.
197. Henson JD, **Vitetta L**, Quezada M, Hall S. Enhancing Endocannabinoid Control of Stress with Cannabidiol. *J Clin Med* 2021;10(24):5852.
198. Chen J, **Vitetta L**. The gut-liver axis in chronic liver disease - associated with severe COVID-19. *Eur J Gastroenterol and Hepatol* 2021;33(15 Suppl 1):e1103.
199. Chen J, **Vitetta L**. Gut Dysbiosis Could Be a Major Factor for the Effects of Low-Grade Endotoxemia in COVID-19. Comment on: Low-Grade Endotoxemia and Thrombosis in COVID-19. *Clin Transl Gastroenterol* 2022;13(1):e00440.
200. Chen J, **Vitetta L**, Henson JD, Hall S. Intestinal dysbiosis, the tryptophan pathway and Nonalcoholic Steatohepatitis (NASH). *International Journal of Tryptophan Research*. 2022; Feb 7;15:11786469211070533.
201. **Vitetta L**, Sikali JF, Fletcher C, Henson JD. Comment on: Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences. *Support Care in Cancer* 2022 Mar 21. doi: 10.1007/s00520-022-06995-7.
202. **Vitetta L**, Andersen T, Quezada M, Rutolo D, Henson JD. Re: "Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial" by Crippa et al. *Cannabis Cannabinoid Res* 2022;7(2):231-233.
203. Henson JD, **Vitetta L**, Hall S. Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. *Inflammopharmacology* 2022; 30(4):1167-1178.
204. **Vitetta L**. Can krill oil from small crustaceans be a panacea that alleviates symptoms of knee osteoarthritis? *Amer J Clin Nutr* 2022;116(3):621-622.
205. Chen J, **Vitetta L**. The role of the gut-lung axis in COVID-19 infections and its modulation to improve clinical outcomes. *Frontiers in Bioscience-Scholar* 2022;14(3):23.
206. Pickering E, Steels EL, Steadman KJ, Rao A, **Vitetta L**. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. *Inflammopharmacology* 2022;30(6):2063-2077.

207. **Vitetta L.** The Vermiform Appendix, Expendable or Essential? A narrative review. *Current Opinions in Gastroenterology* 2022;38(6):570-576.
208. Ritchie G, Strodl E, Parham S, Bambling M, **Vitetta L.** The gut microbiota in major depression with anxious distress. *J Affect Dis* 2022;320:595-604.
209. Clarke S, Butcher BB, McLachlan AJ, Henson JD, Rutolo D, Hall S, **Vitetta L.** Pilot Clinical and Pharmacokinetic Study of Δ^9 -Tetrahydrocannabinol (THC) / Cannabidiol (CBD) Nanoparticle Oro-Buccal Spray in Patients with Advanced Cancer Experiencing Uncontrolled Pain. *PLOS ONE* 2022;17(10):e0270543.
210. Chen J, **Vitetta L.** Is miR-223 upregulation in inflammatory bowel diseases a protective response? *Frontiers in Bioscience-Elite* 2023;15(1):5.
211. **Vitetta L.** Letter on: Role of gut microbiome in immune regulation and immune checkpoint therapy of colorectal cancer *Medical Oncology* 2023;40:401.
212. **Vitetta L,** Bambling M, Strodl E. Probiotics and Commensal Bacteria Metabolites Trigger Epigenetic Changes in the Gut and Influence Beneficial Mood Dispositions. *Microorganisms* 2023;11(5):1334.
213. **Vitetta L,** Gorgani NN, Vitetta G, Henson JD. Prebiotics Progress Shifts in the Intestinal Microbiome that Benefits Patients with Type 2 Diabetes Mellitus. *Biomolecules* 2023; 13 (9):1307.
214. **Vitetta L,** Henson JD. Topical cannabidiol, elite athletes with chronic lower extremity pain. *J Cannabis Research. J Cannabis Res* 2024; 6(1):13.
215. **Vitetta L,** Oldfield D, Sali A. Inflammatory Bowel Diseases and the Efficacy of Probiotics as Functional Foods. *Frontiers in Bioscience-Elite* 2024;
216. Thomsen M, Huygens F, Clarke S, **Vitetta L.** The Effect of a Multi-Species Probiotic Formulation to Prevent Chemotherapy Induced Diarrhoea by Rescuing Gastrointestinal Dysbiosis and Mucositis: A Pilot Study. *Inflammopharmacology* 2024;

Abstracts / Proceedings (x119)

1. Nayman J, **Vitetta L,** Hocking C, Sali A. Primary bile duct stones. *Royal Australasian College of Surgeons Aust NZ J Surg* 52:280-281 1981. Sydney Australia.
2. Sali A, **Vitetta L,** Hocking C, Kune GA, Nayman J. The Composition of primary bile duct stones. 7th World CICD Congress on Gastroenterology. *Digs Surg J* 1:F018, 1982. Tokyo Japan.
3. Sali A, **Vitetta L,** Hocking C, Kune GA. In vitro dissolution of cholesterol gallstones with citrate. 7th World CICD Congress on Gastroenterology. *Digs Surg J* 1:R52, 1982. Tokyo Japan.
4. **Vitetta L,** Sali A, Hocking C, Thomson G. Calcified cholesterol gallstones and citrate. 1st Australian Postgraduate Research Meeting. *APRC Proc* 1, 1983. Sydney Australia.
5. **Vitetta L,** Sali A, Hocking C, Thomson G. Primary bile duct stone composition suggests an etiology different to that of gallbladder stones. 1st Australian Postgraduate Research Meeting. *APRC Proc* 1, 1983. Sydney Australia.
6. Sali A, **Vitetta L,** Hocking C, Thomson G, Kune GA. Dissolution of calcified cholesterol gallstones with citrate. 30th World CISS Conference in Surgery. *World J Surg* 90, 1983. Hamburg Germany.
7. **Vitetta L,** Sali A, Chou ST, Fleming H. Gallstone incidence and composition. *Royal Australasian College of Surgeons. Aust NZ J Surg* 14, 1984. Melbourne Australia.
8. Sali A, **Vitetta L,** Chou ST, Fleming H. Gallstone incidence and composition in Australia. 8th World CICD Congress on Gastroenterology. *Digs Surg J* W047, 1984. Amsterdam.
9. **Vitetta L,** Coloe S, Carsons P, Thomson G, Sali A. The role of bacteria in the etiology of gallstones. *Royal Australasian College of Surgeons. Aust NZ J Surg* 137, 1985. Sydney Australia.
10. **Vitetta L,** Sali A, Moritz V, Shaw A. Gallstones and bacteria. 9th World CICD Congress on Gastroenterology. In: *Dig Surg J* 1986;3(2) :106. Jerusalem Israel 1985. [Dig Surg 1986;3(2):63–198 (DOI:10.1159/000171727)].
11. **Vitetta L,** Sali A, Moritz V, Shaw A. Is the etiology of primary choledocholithiasis unique? 9th World CICD Congress on Gastroenterology. In: *Dig Surg J* 1986;2(3):126. Jerusalem, Israel 1985. [Dig Surg1986;3(2):63–198 (DOI:10.1159/000171727)]
12. **Vitetta L,** Sali A, Little P. Do primary bile duct stones occur in the duct? *Royal Australasian College of Surgeons. Aust NZ J Surg* 209, 1986 Adelaide Australia 1986.
13. **Vitetta L,** Sali A, Elzarka A. Primary bile duct stone etiology: a role for bacterial β glucuronidase. 32nd World CISS Conference in Surgery. *World J Surg* 43, 1987. Sydney Australia.
14. Kune GA, Kune S, Watson LF, Pierce RJ, **Vitetta L,** et al. Serum levels of vitamin A, β carotene and zinc in male lung cancer cases and controls. 14th Annual Meeting Clinical Oncological Society of Australia. *Clin Oncol Soc Aust* 98, 1987 Perth Australia.
15. Pierce RJ, Watson LJ, Kune GA, Kune S, **Vitetta L,** et al. Smoking pattern occupational risk family history dietary and alcohol intake in lung cancer. *Thoracic Society of Australia and New Zealand.* 46, 1987 Perth Australia.
16. RJ Pierce, LF Watson, GA Kune, S Kune, L Vitetta, B Filed, D Merenstein, A Hey, LB Irving. Smoking pattern occupational risk family history dietary and alcohol intake in lung cancer: results of a case control study. *Proceedings of the British Thoracic Society, Scottish Thoracic Society and Thoracic Society of Australia.* 707. In: *Thorax* 1987;42:705-752. University of Edinburgh, Edinburgh, Scotland. 1987.
17. Sali A, **Vitetta L.** Dissolution and decalcification of gallstones with chenodeoxycholate and citrate. *Royal Australasian College of Surgeons Aust NZ J Surg* 250, 1988. Brisbane Australia.
18. Gya D, Sali A, **Vitetta L,** Eu P. Limy bile cholecystitis: a case report and an in vitro study. *Royal Australasian College of Surgeons Aust NZ J Surg* 389, 1989. Melbourne Australia.
19. **Vitetta L,** A Sali. Is infection a cause of cholesterol gallstones. *Royal Australasian College of Surgeons Aust NZ J Surg* 328, 1989. Melbourne Australia.
20. Fukuma E, **Vitetta L,** A Sali. Composition of intrahepatic stones. *Proceedings World Gastroenterology Conference Gastroenterol* 215,1990. Sydney Australia.
21. **Vitetta L,** Moritz V, Mayall B, Sali A. Cholesterol gallstones and bacteria *Royal Australasian College of Surgeons Aust NZ J Surg* 1996;545, Melbourne Australia.

22. **Vitetta L**, Sali A. Gallstones and gallbladder carcinoma Royal Australasian College of Surgeons Aust NZ J Surg 1996;666, Melbourne Australia.
23. **Vitetta L**, Sali A, Moritz V, Mayall B. Bacteria and cholesterol gallstones 15th World CIDC Conference Digs Surg 90, 1996 Seoul South Korea.
24. Gersh W, **Vitetta L**, McEvoy A, Mrazek L, Sali A. A National Needs Assessment of Parents of Children with Inflammatory Bowel Disease 7th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology and Nutrition Proceedings in Paediatrics Cairns Australia 2001.
25. **Vitetta L**, Sali A, Paspaliaris B, Liltle P, Jones T. Cholesterol Solitaire Gallstones and Bacterial Infections. 4th Congress of the European chapter of the international HPB Association Proceedings HBP 3(1):26 Amsterdam 2001.
26. **Vitetta L**, Sali A, Little P, Jones T. Brown Pigment Gallstones and Cholesterol Precipitates 4th Congress of the European chapter of the international HPB Association Proceedings HBP 3(1):26 Amsterdam 2001.
27. **Vitetta L**, Sali A, Jones T, Little P. Brown pigment gallstone formation: bacteria and precipitates of mucous, pigment and cholesterol. 18th World Congress and 9th Hong Kong International Cancer Congress. Hong Kong 2002.
28. **Vitetta L**, Cortizo F, J, Walker R, Rollo D, Sali A. Primary Care Cardiovascular Prevention: A System Using Absolute Risk, Pulse Wave Velocity, Heart Rate Variability, Blood Pressure and an Electrocardiogram. 25th Scientific Meeting of the Inter-American Society of Hypertension. 27-30 April 2003 San Antonio, US.
29. Reavley N, **Vitetta L**, Cortizo F, Sali A. A preliminary report of the effect of psychosocial support on the psychological and physical wellbeing of a heterogeneous group of cancer patients. Psycho Oncology 2004; 13: S51.
30. Thomsen M, Flannery G, **Vitetta L**, Schmidt M, Sali A. Herbal Preparation - Ginseng / Dang Gui Ten Combination (PS10) and Immune Response in Humans. International Congress on Natural Products Research (ICNPR) Proceedings 2004. Phoenix US.
31. Reavley N, **Vitetta L**, Cortizo F, Sali A. A preliminary report of the effect of psychosocial support on the psychological and physical wellbeing of a heterogeneous group of cancer patients – a further update. Australian Resource Centre for Healthcare Innovations Conference. 2004. Gold Coast Australia.
32. Di Vincenzo R, **Vitetta L**, Ng F, Cortizo F, Sali A. Nutritional and lifestyle factors influencing the development and progression of NIDDM in lean adult Vietnamese. Australian Resource Centre for Healthcare Innovations Conference. Gold Coast Australia 14-15th October 2004.
33. Harris E, Pipingas A, Kirk J, **Vitetta L**. The effect of multivitamin supplementation on cognition in adults at risk of cognitive decline. 15th Australasian Society for Psychophysiology Conference–Wollongong, Australia. In Journal of EEG and Clinical Neuroscience. Wollongong, Australia, 9-11th December 2005.
34. Pipingas A, Silberstein R, **Vitetta L**, Van Rooy C, Nastase J, Sali A. The Effects of an Extract of *Pinus Radiata* Pine Bark (Enzogenol) on Cognitive Function in Individuals at Risk of Cognitive Decline. 15th Australasian Society for Psychophysiology– Wollongong, Australia. In Journal of EEG and Clinical Neuroscience. Wollongong, Australia 9-11th December 2005.
35. Wang Y, Cicuttini FM, **Vitetta L**, Wluka AE What effect do dietary antioxidants have on the symptoms and structural progression of knee osteoarthritis over 2 years? Annual Scientific Meeting of the Australian Rheumatology Association, Melbourne 2005. Internal Medicine Journal 2005 (Suppl.):35:A89–A116.
36. Harris E, Pipingas A, Kirk J, **Vitetta L**, Downey LA. The Effects of Multivitamin Supplementation on Cognition in Adults at Risk of Cognitive Decline. 7th International Conference and Exhibition on Nutraceuticals and Functional Foods. Reno US, November, 2006.
37. **Vitetta L**, Sali A, Reavley N. Positive Thinking, Diet, Meditation and Psychosocial Support and Its Effects On The Psychological And Physical Wellbeing Of Cancer Patients. 3rd International Congress on Complementary Medicine Research, 29-31 Mar 2008. Sydney, Australia. S90.
38. **Vitetta L**, Poon HY, Sali A. HIV/AIDS and Complementary and Alternative Medicine (CAM) A Clinical Trial With A Traditional Chinese Medicine (TCM) / Yeast Preparation. 3rd International Congress on Complementary Medicine Research. 29-31 Mar 2008. Sydney, Australia.
39. Harris E, Kirk J, Vitetta L, Sali A, Pipingas A. Improvement of depressive symptoms in the elderly following multivitamin supplementation. 3rd International Congress on Complementary Medicine Research. 29-31 Mar 2008. Sydney, Australia S35.
40. **Vitetta L**, Harris E, Kirk J, Pipingas, A Sali A. Cognitive Decline in at Risk Adults and the Effect of a Multivitamin/Mineral Supplement. Heart Foundation Conference 14-16 May 2009 Brisbane, Australia. P109.
41. Coulson S, **Vitetta L**. Green–Lipped Mussle Extract and GIT Function in Patients Diagnosed with OA of the Knee. In:15th International Holistic Health Conference. Melbourne, Australia, 9-11 October 2009.
42. **Vitetta L**. Mitochondrial Metabolism, Nutraceuticals and Cognitive Decline with Ageing. In: 15th International Holistic Health Conference. Melbourne, Australia, 9-11 October 2009.
43. Schoendorfer N, **Vitetta L**, Boyd R, Davies PSW. Is the methyl folate trap responsible for growth stunting found in children with severe cerebral palsy? 50th Annual Meeting of the European Society for Paediatric Research Acta Paediatrica 2009;98 Suppl 460: 230. Hamburg, Germany, 9-12 Oct 2009.
44. Schoendorfer N, Tinggi U, Boyd R, **Vitetta L**, Davies PSW. Micronutrient intakes in children with cerebral palsy. [19th International Congress of Nutrition] Annals of Nutrition and Metabolism 2009;55 Suppl 1: 481.
45. Schoendorfer N, Boyd R, **Vitetta L**, Tinggi U, Coombes J, Davies PSW. Micronutrient status in children with cerebral palsy and the impact of a major orthopaedic surgical intervention. [19th International Congress of Nutrition] Annals of Nutrition and Metabolism 2009;55 Suppl 1: 484.
46. Schoendorfer N, Boyd R, **Vitetta L**, Tinggi U, Coombes J, Davies PSW. Micronutrient status in children with cerebral palsy [Nutrition Society of Australia and Nutrition Society of New Zealand. Thirty-third Annual Scientific Meeting]. 8-11 Dec, 2009 Newcastle, Australia. Australasian Medical Journal 2010; 3(1):55.
47. Schoendorfer N, Boyd R, **Vitetta L**, Tinggi U, Coombes J, Davies PSW. Micronutrient status in children with cerebral palsy. 5th Biennial Conference of the Australasian Academy of Cerebral Palsy & Developmental Medicine [Developmental Medicine and Child Neurology-Special Issue] Christchurch, NZ 3-6 Mar 2010; 52 Suppl 2:47.
48. Coulson S, Beck S, Gramotnev H, Masci P, **Vitetta L**. A Randomised Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of a Lactoferrin / Whey Protein Ig–Rich Fraction to Prevent the Onset of a Cold or Reduce Time of Symptoms in Patients with a Cold. In: 16th International Holistic Health Conference, Sunshine Coast, Australia, 3-5 September, 2010.
49. Schloss J, Colosimo M, Linnane AW, Masci P, **Vitetta L**. A Pilot Clinical Trial Assessing the efficacy and Safety of supplementation with vitamin B12 and other B vitamins to reduce the incidence of chemotherapy induced peripheral neuropathy [CIPN] in patients diagnosed with a malignancy. In: 16th International Holistic Health Conference, Sunshine Coast, Australia, 3-5 September, 2010.

50. Chen CF, Zhao KN, Linnane AW, Masci P, **Vitetta L**. The *in vitro* and *in vivo* effects of pharmacologic doses of ascorbate on cancer. In: 16th International Holistic Health Conference, Sunshine Coast, Australia, 3-5 September, 2010.
51. Gray B, **Vitetta L**, Coulquon D, Masci P. Marine Lipid Supplementation. Obesity: The Effect On Adiponectin And Leptin. In: 19th annual RBWH Health Care Symposium. Brisbane 2010.
52. Schoendorfer N, Tinggi U, Sharp N, **Vitetta L**, Davies PSW. Does enteral feeding compare with orally fed children with cerebral palsy or typically developing children? Nutrition Society of Australia thirty-fourth Annual Scientific Meeting [Australasian Medical Journal] 30 Nov-3 Dec 2010;3(13):880.
53. **Vitetta L**. The role of intravenous [IV] Vitamin C [Ascorbate] in the therapeutic treatment of Cancer. 1st International Conference on the Science of Nutrition in Medicine and Healthcare. May13-15;2011;71-72. Sydney, Australia.
54. **Vitetta L**. Probiotics: An Update. 1st International Conference on the Science of Nutrition in Medicine and Healthcare. May13-15;2011;72. Sydney, Australia.
55. Chen C, Zhao KN, Masci P, Linnane AW, **Vitetta L**. Mathematical Modelling and Molecular Mechanism of Pharmacologic Ascorbate-Induced Cytotoxicity in Cancer Cells. 1st International Conference on the Science of Nutrition in Medicine and Healthcare. May 13-15;2011;78. Sydney, Australia.
56. Coulson S, Vecchio P, Masci P, **Vitetta L**. A Randomized Phase-I/Pilot Comparison Trial Evaluating the Efficacy of Nutraceutical Compounds In Patients With Osteoarthritis Of The Knee – Therapeutic Outcome Measures Correlated To Gastrointestinal Integrity. 1st International Conference on the Science of Nutrition in Medicine and Healthcare. 2011;80. May13-15. Sydney Australia.
57. Gray B, **Vitetta L**, Colquhoun D, Masci P. Omega-3 Fatty Acid Supplementation In Obesity: The Effect On Adiponectin, Leptin And Insulin Sensitivity. 1st International Conference on the Science of Nutrition in Medicine and Healthcare. May 13-15;2011;86. Sydney Australia.
58. Schloss J, Colosimo M, Linnane AW, Masci P, **Vitetta L**. A Randomised Placebo Controlled Clinical Trial Assessing The Efficacy And Safety Of Supplementation With B Vitamins To Reduce The Incidence Of Chemotherapy Induced Peripheral Neuropathy [CIPN]. 1st International Conference on the Science of Nutrition in Medicine and Healthcare. May 13-15;2011;104. Sydney, Australia.
59. Schoendorfer N, Schafer J, **Vitetta L**, Davies, PW. Nutrition Integration into MBBS Programme: A Pilot Project. 1st International Conference on the Science of Nutrition in Medicine and Healthcare. May 13-15;2011;105. Sydney, Australia.
60. Shing CM, Peake JM, Lim F, Briskey D, **Vitetta L**. Response to exercise in the heat following a period of probiotics supplementation. 16th Congress of the European College of Sports Science in Liverpool July 6-9, 2011.
61. Shing CM, Peake JM, Lim F, Briskey D, **Vitetta L**. Response to exercise in the heat following a period of probiotics supplementation. 10th Symposium of International Society of Exercise and Immunology in Oxford in July 11-13, 2011.
62. Sali A, Pipingas A, Harris E, Kirk J, **Vitetta L**. Use of a Multivitamin, Mineral and Herbal Supplement to improve Memory, Mood and Stress. 4th European Congress for Integrative Medicine. Berlin, Germany, Oct 7-8 2011.
63. Coulson S, Vecchio P, Butt H, Masci P, **Vitetta L**. Investigating Gastrointestinal Function And Microbiota Profiles In Patients With Osteoarthritis – A Role For Glucosamine And Green-Lipped Mussel. World Congress on Debates and Consensus in Bone, Muscle and Joint Diseases. Barcelona, Spain January 19-22, 2012.
64. **Vitetta L**. Probiotics and the Gastrointestinal Tract Microbiome in Musculoskeletal Disease. 2nd International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
65. **Vitetta L**, Coulson S, Beck SL, Gramotnev H, Du S, Lewis S. Bovine Lactoferrin / Whey Protein Ig-rich Fraction (Lf/IgF) Combination for the Common Cold: A Randomized Placebo Controlled Clinical Trial. 2nd International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
66. Briskey D, Heritage ML, Jaskowski LA, Fletcher LM, Subramaniam VN, Anderson GJ, Crawford DHG, Peake J, **Vitetta L**. A Multi-Strain Probiotic Retards Non-Alcoholic Fatty Liver Disease Progression In Mice Fed A High Fat Diet. 2nd International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
67. Coulson S, Vecchio P, Butt H, Masci P, **Vitetta L**. Metabolic Potential Of Gastrointestinal Microbiota Profiles In Patients With Osteoarthritis – Implications For The Therapeutic Activity Of Glucosamine And Green-Lipped Mussel. 2nd International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
68. Chen C, Zhao KN, Masci P, Linnane AW, **Vitetta L**. Molecular Mechanisms of Pharmacologic Ascorbate-induced Cytotoxicity in Cancer Cells. 2nd International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
69. Gray B, Colquhoun D, Steyn D, Russell A, Muhlhauser B, **Vitetta L**. Reducing Fatigue in Obesity: An Observational Study Investigating The Potential Role Of Omega-3 Essential Fatty Acids. 2nd International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
70. Schoendorfer N, Obeid R, Sharp N, **Vitetta L**, Boyd R, Davies P. Altered DNA methylation and one-carbon metabolism: A case for the methyl-folate trap? 2nd International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
71. Martensen R, Coulson S, Isenring E, **Vitetta L**. Reducing the risk of developing *Clostridium difficile* infections/diarrhoea by co-prescribing a multi-strain probiotic with proton pump inhibitor [PPIs] medications. In: 18th International Integrative Medicine Conference, Melbourne, Australia, 31 Aug–2 Sep, 2012.
72. Coulson S, Butt H, Vecchio P, Gramotnev H, **Vitetta L**. Gastrointestinal Microbiota Profiles in Patients with Osteoarthritis – Implications for the Therapeutic Activity of Green-Lipped Mussel (*Perna canaliculus*) and Glucosamine. In: 18th International Integrative Medicine Conference, Melbourne, Australia, 31 Aug–2 Sep, 2012.
73. **Vitetta L**. Gastrointestinal Dysbiosis and Probiotics in Musculoskeletal Medicine In: 18th International Integrative Medicine Conference, Melbourne, Australia, 31 Aug–2 Sep, 2012.
74. Palacios T, Coulson S, Butt H, Leong G, Dahiya R, **Vitetta L**. Gut Microbiota and Metabolic Syndrome: How a Multi-Strain Probiotic may Influence Biomarkers in Obese Adolescents. 3rd International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.
75. Coulson S, Palacios T, Butt H, Leong G, Dahiya R, **Vitetta L**. The Role of Gut Microbiota in Non-Alcoholic Fatty Liver Disease: The Efficacy of a Multi-Strain Probiotic in Obese Adolescents. 3rd International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.

76. Steels E, Rao A, Coulson S, **Vitetta L**. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. 3rd International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.
77. Schloss J, Colosmio M, Linnane AW, Masci P, **Vitetta L**. B Vitamin Status In Cancer Patients Administered Chemotherapy. 3rd International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.
78. Marx W, Ried K, Sali A, Teleni L, McCarthy A, **Vitetta L**, McKavanagh D, Thomson D, Isenring E. Is Ginger Supplementation Effective In Ameliorating Chemotherapy-Induced Nausea And Vomiting? 3rd International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.
79. Schloss J, Colosmio M, Linnane AW, Masci P, **Vitetta L**. A Randomised Placebo-Controlled Clinical Trial Assessing The Efficacy And Safety Of Supplementation With B Vitamins To Reduce The Incidence Of Chemotherapy-Induced Peripheral Neuropathy [CIPN], Final Results. 4th International Conference on the Science of Nutrition in Medicine and Healthcare. 2014; May 3-5. Gold Coast, Australia.
80. Palacios T, Coulson S, Butt H, **Vitetta L**. The Effect Of Microbiota-Based Interventions And Metformin In Metabolic And Inflammatory Biomarkers In Adults With Type 2 Diabetes Mellitus (T2DM). 4th International Conference on the Science of Nutrition in Medicine and Healthcare. 2014; May 3-5. Gold Coast, Australia.
81. Marx W, McCarthy AL, Ried K, **Vitetta L**, McKavanagh D, Thomson D, Sali A, Isenring L. Ginger-Mechanism Of Action In Chemotherapy-Induced Nausea And Vomiting: A Review. 4th International Conference on the Science of Nutrition in Medicine and Healthcare. 2014; May 3-5. Gold Coast, Australia.
82. **Vitetta L**. The gastrointestinal tract microbiome and the metabolism of herbal compounds such as *trigonella foenum-graecum* extract. The 4th International Symposium on Curry and Spice (April 24, 2014) in Seoul, South Korea.
83. **Vitetta L**. Probiotics, the gastrointestinal tract microbiome and musculoskeletal diseases. International Probiotic Association World Congress. May 9-10, 2014, Athens, Greece. In: Beneficial Microbes 5 (Suppl 1): 23.
84. Schloss J, Colosimo M, Airey C, Masci PP, Linnane AW, **Vitetta L**. B complex vitamins reduce the onset and severity of chemotherapy induced sensory peripheral neuropathy. 7th International Conference and Exhibition on Nutraceuticals and Functional Foods. October 14-17, 2014, Istanbul, Turkey.
85. Marx W, Ried K, McKavanagh D, **Vitetta L**, Sali S, Isenring L. Ginger as an adjuvant for chemotherapy-induced nausea and vomiting: where does the evidence stand? Asia Pacific Journal of Clinical Oncology 2014;10:115-116.
86. Rao A, Steels E, **Vitetta L**, Inder W, Beccaria G. Influence of a specialized Trigonella foenum-graecum seed extract (Libifem), on testosterone, estradiol and sexual function, a randomized placebo-controlled study. 25th Annual Meeting of The North American Menopause Society October 15–October 18, 2014, Washington, DC. In: Menopause 21(12):1360-1361.
87. Briskey D, Peake J, Coulson S, **Vitetta L**. High Fat Diet, Probiotics and Non-Alcoholic Fatty Liver Disease 4th Beneficial Microbes Conference, The Hague, Netherlands, 2015, 75, P25.
88. Marx W, Ried K, Sali A, **Vitetta L**, McKavanagh D, McCarthy A, Thomson D, Isenring L. Can ginger improve chemotherapy-induced nausea and vomiting related quality of life? The 5th Science of Nutrition in Medicine and Healthcare Conference, Melbourne, May 2-3, 2015; 68.
89. Schloss J, Colosimo M, Airey C, Linnane AW, Masci P, **Vitetta L**. Chemotherapy induced neuropathy (CIPN) and vitamin B12 deficiency. The 5th Science of Nutrition in Medicine and Healthcare Conference, Melbourne, May 2-3, 2015; 74.
90. RJ Ellis, DM Small, KL Ng, DA Vesey, **L Vitetta**, R Francis, C Morais, GC Gobe. Indoxyl Sulphate Induces Hypertrophy and Impaired Metabolic Activity In Cultured Human Proximal Tubular Cells. Aust New Zealand Soc of Nephrol (Annual Scientific Meeting) 2015; Sep 7–9. Canberra, Australia.
91. **Vitetta L**. Reactive oxygen species and their lifelong regulation of the metabolome. 6th World Congress on Targeting Mitochondria. Oct 28–30, 2015. Berlin, Germany.
92. **Vitetta L**. A multi-strain probiotic preparation in a mouse model of a high fat diet / obesity induced liver steatosis. 5th Annual Science of Nutrition in Medicine and Healthcare Conference. May 2-3, 2015. Melbourne, Australia.
93. Palacios T, **Vitetta L**, Coulson S, Butt H, Caterson I. The Effect of a Multi-Strain Probiotic on Metabolic Bio-Markers in Adults with Prediabetes and Recently Diagnosed Type 2 Diabetes Mellitus (T2DM). ICO May 1-4, 2016, Vancouver, Canada.
94. **Vitetta L**, Palacios T, Coulson S, Caterson ID. The administration of multi-species probiotics that shifts the intestinal microbiome to improve metabolic inflammatory biomarkers in adults with pre-diabetes and type 2 diabetes mellitus (T2DM). RACGP, Perth Oct 2016.
95. Chen T, Ellis R, Morais C, Gobe G, **Vitetta L**. Nephrotoxic effects of cis-diamminedichloroplatinium II (cisplatin) can be ameliorated using Coenzyme Q10 (CoQ10), 7th World Congress on Targeting Mitochondria. Oct 24–26, 2016. Berlin, Germany.
96. Palacios T, Caterson I, Madigan C, **Vitetta L**. The Efficacy of a Novel Probiotic on Glucose Metabolism: A Randomised Controlled Trial. The 4th Latin American Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension. 16-18 Mar 2017. Buenos Aires, Argentina.
97. **Vitetta L**. The intestinal microbiome, metabolic diseases and probiotics. BIT 15th International Conference: IDDST Jul 26-28 2017. Osaka, Japan.
98. **Vitetta L**. Mood disorders cognition and the intestinal mucosa. Australian Society of Lifestyle Medicine 15-17 Sep 2017. Sydney, Australia.
99. Kalma B, Ellis RJ, **Vitetta L**, Wood ST, Gobe GC. Pilot Study: Urinary Indoxyl Sulphate As A Predictor Of Postoperative Kidney Function Following Radical Tumour Nephrectomy. 54th Australian and New Zealand Society of Nephrology. Annual Scientific Meeting 8-12 Sep 2017. Sydney, Australia.
100. Palacios T, **Vitetta L**, Madigan C, Caterson I. The development of a evidence-based probiotic formulation and its efficacy in obesity and type 2 diabetes. 4th Beneficial Microbes Conference, 9-11 Oct 2017. Amsterdam, The Netherlands
101. **Vitetta L**. Cancer Treatments, the Intestinal Microbiome and Probiotics. IPA World Congress | Asia Probiota. 11-13 Oct 2017. Singapore.
102. Palacios T, **Vitetta L**, Madigan C, Caterson I. Prediabetes and Early Diagnosed T2DM: safety tolerability and pilot exploratory study preliminary results. 5th MICROBIOME R And D And BUSINESS COLLABORATION FORUM: USA COLLABORATIONS IN MICROBIOME RESEARCH, LIVE BACTERIAL THERAPEUTICS, HUMAN HEALTH & DISEASE | 2nd PROBIOTICS CONGRESS: USA. 2-3 Nov 2017. San Diego, USA.
103. Thomsen M, **Vitetta L**. Optimising the Gut Microbiome: Adjuvant Treatments/Therapies. Clinical Oncological Society of Australia; Pre-Conference Workshop Nov 12 2017. Sydney, Australia

104. **Vitetta L**, Clarke S, Thomsen M. The intestinal microbiome, chemotherapy and adjuvant treatments with probiotics. *Asia-Pacific Journal of Clinical Oncology* [Clinical Oncological Society of Australia] 2017; Nov 13-15; 13(4):98, ABS#105. Sydney, Australia.
105. **Vitetta L**. The intestinal microbiome, cancer treatments and adjuvant probiotics. 4th Annual Symposium. *Integrative Medicine: The Art and Science*. 24-25 Nov 2017. Melbourne, Australia.
106. Palacios T, **Vitetta L**, Coulson S, Madigan CD, Caterson ID. A novel probiotic for glucose management: A randomized double-blind placebo-controlled pilot study. *Obesity Research and Clinical Practice* 2019;13(1):99-100.
107. Palacios T, **Vitetta L**, Caterson I, Kim JN, Soto-Giron M, Ishoey T, Toledo T, Soto J, Schott EM, Briskey D, Madigan C, Coulson S, Lam Y, Hall S. A randomised controlled pilot study to investigate the effect of a multi-species probiotic formulation and metformin as modulators of the intestinal microbiome for the management of diabetes. *Nutrients* 2019–In *Nutritional Advances in the Prevention and Management of Chronic Disease*, Sept 25-27; Barcelona, Spain.
108. **Vitetta L**. Mood Disorders and the Brain–Intestinal Mucosa–Appendix–Microbiome–Brain Loop. Keynote Invitation. Probiota Asia Conference, Singapore, 22-24 Oct 2019.
109. Thomsen M, **Vitetta L**, Clarke S. Intestinal microbiome and chemotherapy-induced neutropenia. *Clinical Oncological Society of Australia Scientific Conference*, Adelaide, 12-14 Nov 2019.
110. **Vitetta L**, Clarke S, McLachlan AJ, Henson J, Fletcher C, Vitetta G, Rutolo D, Hall S. A Novel Delivery Mechanism for Cannabinoids in Pain Management. *Clinical Oncological Society of Australia Scientific Conference*, Adelaide, 12-14 Nov 2019.
111. **Vitetta L**. The Brain-Intestinal Mucosa-Appendix-Microbiome-Brain Loop. *Australian Pharmaceutical Professional Conference*. Gold Coast Convention and Exhibition Centre. 19-22 Mar 2020.
112. **Vitetta L**, Henson HD, Rutolo R, Hall S. An oro-buccal nanoparticle-cannabis delivered medicine for pain management in cancer. 9th Global Nanotechnology Congress and Expo. Miami, Florida, USA. 13-14 Apr 2020.
113. Clarke S, Butcher B, McLachlan AJ, Henson JD, Rutolo D, Hall S, **Vitetta L**. Can improved mucosal absorption allow a THC/CBD oro-buccal spray to achieve clinical efficacy in chronic pain? ANZCA ASM Poster (Anaesthesia and Pain Medicine in Australia and New Zealand) 30th Apr- 4th May Melbourne 2021.
114. Chen J, **Vitetta L**. Butyrate Sensitizes Epithelioid Mesothelioma Cells to Oxaliplatin. 15th Meeting of the International Mesothelioma Interest Group-Virtual. Poster. In section: Mesothelioma Biology and Novel Targets | 306 (iMig 2021) May 7–9, 2021.
115. Sikali JF, Fletcher C, Gillespie A, Hall L, Henson JD, Hall S, **Vitetta L**, and the Medical Science Liaison Team at Medlab Clinical. An Observational Study Investigating And Auditing The Safety, Tolerability And Further Efficacy Characteristics Of A Pharmaceutical Grade Cannabis-Based Medicine Prescribed To Eligible Patients For The Management Of Cancer Related Or Non-Cancer Related Pain In General And Specialty Medical Practices Australia-Wide. 48th Annual Scientific Meeting COSA 16-18th November, Brisbane 2021.
116. Clarke S, Butcher B, McLachlan AJ, Henson JD, Rutolo D, Hall S, **Vitetta L**. Can improved mucosal absorption allow a THC/CBD oro-buccal spray to achieve clinical efficacy in chronic pain? *Australian Pain Society* 19-20th April 2022, Hobart.
117. Clarke S, Butcher BE, McLachlan AJ, Hendon JD, Rutolo D, Hall S, **Vitetta L**. Can oral administration provide a suitable plasma cannabinoid profile for the effective treatment of chronic pain? *IASP World Congress on Pain* 19-23 September 2022, Toronto Canada.
118. Henson JD, **Vitetta L**, Fletcher C, Lu C, Quezada, M Moroni I, Andersen T, Hall S. Can oral administration provide a suitable plasma cannabinoid profile for the effective treatment of chronic pain? *IASP World Congress on Pain*. Toronto, Canada. 2022.
119. Byun AS, **Vitetta L**, Chan HK, Kwok PCL. Nebulisation of *Lactobacillus rhamnosus* GG with vibrating mesh and jet nebulisers. *Asian Federation for Pharmaceutical Sciences* 2023 | Nov 8-10, 2023, Hanoi Vietnam.